System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients
To access this article, please choose from the options below
Supported in part by the John R. Grey IV Cardiology Fellowship Fund at Children's Hospital, Department of Cardiology. Dr. Cecchin has received consulting fees and speaker honoraria from St. Jude Medical and Boston Scientific. Dr. Triedman has received consulting fees from Biosense Webster and Boston Scientific. Dr. Walsh has received speaker honoraria from St. Jude Medical and Boston Scientific.
PII: S1547-5271(09)01178-3
doi:10.1016/j.hrthm.2009.10.014
© 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
